Independent analysis of commercial transformation across life sciences in Europe

Life Sciences Commercial Transformation in Europe — Strategy, Market Signals, and What Comes Next

Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.

Read the Weekly Signal About Piotr Wrzosinski

Weekly Life Sciences Signal

Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.

• Weekly Signal

  Europe Life Sciences Weekly Signal #37: When the Operating Layer Becomes the Strategy

  ByPiotr Wrzosinski 17/05/202617/05/2026

  Week of 11–17 May 2026 The procedural week was supposed to be quiet. It was anything but. Bristol Myers Squibb committed up to $15.2 billion to Hengrui across 13 early-stage programmes. Roche bought deeper into AI diagnostics. Bayer’s Q1 numbers showed the commercial cost of patent-cliff transition in plain sight. NICE recommended AstraZeneca’s Imfinzi for…

• Weekly Signal

  Europe Life Sciences Weekly Signal #36: Buying Capability, Earning the Outcome

  ByPiotr Wrzosinski 10/05/202610/05/2026

  Week of 4–10 May 2026 Capability can be bought faster than it can be built. That was the clearest signal in European life sciences this week. Roche moved to acquire PathAI and bring more of the digital pathology workflow inside the diagnostics business. UCB spent up to $2.2 billion to buy into T-cell engagers for…

• Weekly Signal

  Europe Life Sciences Weekly Signal #35: Access Plumbing Becomes Strategy

  ByPiotr Wrzosinski 03/05/202603/05/2026

  Week of 27 April–3 May 2026 Europe had a useful reality check this week. The strongest signals did not come from glossy AI claims, minor partnerships dressed up as strategy, or another ceremonial innovation slogan. They came from the machinery beneath growth: pricing, launch sequencing, regulatory support, evidence expectations, operating-model discipline, and whether Europe can…